Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2015-06-09 Director's Dealing
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2015-06-09 English
FORM 4 SUBMISSION
Director's Dealing
2015-06-09 English
FORM 4 SUBMISSION
Director's Dealing
2015-06-09 English
FORM 4 SUBMISSION
Director's Dealing
2015-06-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a multi-year research collaboration agreement between Organovo Holdings, Inc. and Merck Sharp & Dohme Corp. There are no financial statements, earnings data, or detailed management discussion. The document is relatively short (2747 characters) and serves as a disclosure of a material event rather than a full report. This fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous filings that do not fit other specific categories like earnings releases or annual reports.
2015-04-22 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 21, 2015, by Organovo Holdings, Inc. It announces preliminary unaudited financial information for the fourth fiscal quarter and fiscal year ended March 31, 2015. The document includes a press release as an exhibit. The content is an initial announcement of quarterly and annual financial results, which aligns with the definition of an Earnings Release (ER). The document length is 2917 characters, which is short but contains the actual announcement of financial results, not just a notice of report publication. Therefore, it is classified as an Earnings Release (ER).
2015-04-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.